Alternative approach to treating malignant glaucoma after trabeculectomy with unplanned zonulectomy
Naoki Ozeki1, Kenya Yuki1, Itaru Kimura1,2
1Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan, 2Department of Ophthalmology, Juntendo University Urayasu Hospital, Chiba, Japan
Purpose: To report the role of Healon5TM injection combined with medications in patient with malignant glaucoma after trabeculectomy with unplanned zonulectomy.
Methods: Two days after trabeculectomy with unplanned zonulectomy for neovascular glaucoma in an eye with diabetic retinopathy, a patient developed malignant glaucoma due to the ciliovitreal block caused by the vitreous herniation through the peripheral iridectomy to the limbal incision with flat bleb and anterior chamber, and the intraocular pressure was elevated to 33 mmHg. The medications for the management of malignant glaucoma failed to relieve the malignant mechanism, and Healon5TM, a viscoadaptive, viscoelastic, and ophthalmic viscosurgical device, was injected through a paracentesis until the anterior chamber became deep enough to block the vitreous herniation to the limbal incision.
Results: After Healon5TM injection, the intraocular pressure was reduced enough that the bleb was re-formed, and the anterior chamber remained deep, even without medication.
Conclusions: In patients presenting with malignant glaucoma after trabeculectomy with unplanned zonulectomy, Healon5TM injection, combined with medications, may be a safe and effective approach before performing vitrectomy.
Keywords: malignant glaucoma, unplanned zonulectomy, ophthalmic viscosurgical device, corneal endothelial cell
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.